, /PRNewswire/ — BioLife Solutions, Inc. (Nasdaq: BLFS) (“BioLife” or the “Company”), a leading developer and supplier of bioproduction tools and services for the cell and gene therapy (CGT) market, announces the appointment of Tony J. Hunt, Executive Chairman of Repligen Corporation (Nasdaq: RGEN) and a recognized leader in bioprocessing innovation, to its board of directors effective January 2, 2025. His appointment increases board membership to six.
“Tony is highly respected in the life sciences industry with decades of accomplishments, and it is an honor he has agreed to serve on our board,” said Roderick de Greef, Chairman and CEO of BioLife. “He brings to BioLife an impressive record of success in our sector that culminated in establishing Repligen as a technology leader in bioprocessing. While at Repligen, he led the company to consistently exceed industry revenue growth through a strategy of disciplined acquisitions, internal product development and commercial execution. We look forward …